Researchers at AHA meeting report statin discontinuation in older adults without prior heart attack or stroke met noninferiority but curves favored continued therapy
A randomized trial presented at the American Heart Association meeting found that older adults without prior heart attacks or strokes who stopped statins met a noninferiority threshold, but the curves separated in favor of continued therapy. The result matters because deprescribing decisions affect many older adults, and noninferiority does not automatically mean stopping is safe for all patients.
According to a STAT report, investigators presented STREAM at the American Heart Association's annual meeting as a randomized trial testing whether older adults without a history of heart attacks or strokes could stop statins. The trial compared discontinuation with continued statin therapy and reported that outcomes were not significantly different between the groups. However, the event curves separated during follow-up, with people who stopped statins faring worse than those who continued, a pattern described as noninferior but still unfavorable.
The evidence is preliminary: it was presented at a major cardiology meeting, and the STAT account did not indicate that a full peer-reviewed report had been published. The account did not specify funding. In noninferiority designs, researchers define a margin: a treatment can be statistically similar without being identical. STREAM met that technical threshold, but the Kaplan-Meier curves diverged, suggesting more events among patients assigned to stop statins. The data safety monitoring board reportedly suggested that patients who had stopped their statins discuss resuming them with their doctors.
Statin guidelines have long emphasized continuous treatment for many older adults, especially when risk factors are present, because randomized trials in primary prevention show reductions in heart attacks, strokes and cardiovascular death. STREAM addresses a different question: whether some people already on statins can be taken off without harm. The tension is between population-level evidence and individualized deprescribing. For people with low short-term risk, stopping may be reasonable; for others, the separated curves suggest that stopping may forfeit benefit.
The stakes are large because statins are widely used in older adults, and deprescribing decisions affect millions of medication lists, clinician trust and patient anxiety. This randomized trial design can show whether stopping is statistically noninferior under a predefined margin, but it cannot prove that discontinuation is safe for every individual, especially if curves diverge. Full publication with event counts, hazard ratios, adverse effects and subgroup results is needed to interpret which patients may safely stop.
Older adults taking statins for prevention, and the clinicians managing their medications, face decisions about whether stopping is safe; the trial's noninferior result does not settle that question for everyone.
Sources (1)
- [1]STAT: Opinion: STAT+: I'm a cardiologist. I'm a little puzzled about the blockbuster new study on deprescribing statins(https://www.statnews.com/2026/11/19/deprescribing-statins-study-stream-trial-aha-questions/?utm_campaign=rss)